New data from GoodRx Research reveals just how inadequate and restrictive prescription insurance has become. Medicaid, often ...

Using market access data from day one of your drug development and commercialization journey will help you and your team create a roadmap to success and avoid unforeseen challenges that could ...

The drugs can cost more than $13,600 per patient per year, and the potential market is large: Approximately 142 million adults nationwide meet the Food and Drug Administration’s prescription ...

Appeals court appears likely to restrict access to key abortion pill. Judges aggressively question lawyers for Justice Dept. and drug company about the FDA’s regulation of mifepristone ...

New restrictions on access to a drug used in the most common form of abortion would be imposed under a federal appeals court ruling, but the Supreme Court will have the final say. Skip to content ...

The abortion pill mifepristone will remain on the market for now -- but come Saturday morning, access will be severely restricted while the Biden administration asks the Supreme Court to intervene ...

Inpatient drug launches come with unique market access challenges. Unlike outpatient drugs with revenue potential, inpatient drugs are usually bundled into Diagnosis-Related Group (DRG) payments. This ...

A new study found that almost all plans in 40 states and Washington, DC covered at least one form of the opioid overdose ...

Health & Science Abortion drug mifepristone allowed to stay on market, but with hefty restrictions, ruling says. While the order would keep the drug on the market, it would limit use to 7 weeks ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...